Valence 로고
인기
로그인
Loading data for MGTX — first visit, this takes a few seconds.

관심목록에 추가

MeiraGTx

NasdaqGS: MGTX · 실시간 가격 · USD
13.82
-0.32 (-2.26%)
종가 기준: Aug 28, 2026, 8:00 PM
13.82
+0.00%
애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

MeiraGTx(MGTX) 주가, 분석 및 데이터

-2.26%

데이터 없음

매수호가13.85
시가총액1.33B
매출 (ttm)397.5M
순이익 (ttm)78.98M
1.25
0.87
15.89
-9.94
P/B (ttm)6.04
P/S (ttm)3.34
실적 발표일Nov 12, 2026
매도호가17.57
거래량914,207
평균 거래량 (20일)839,225
시가13.93
전일 종가14.14
일중 범위13.65 - 14.09
52주 범위6.62 - 15.35
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

MGTX 소개

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GA...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Jun 8, 2018
직원 수 393
상장 거래소 NasdaqGS
티커 MGTX
웹사이트 https://www.meiragtx.com
전체 기업 정보

재무 실적

2025년 MeiraGTx의 매출은 81.39M로, 전년 33.28M 대비 144.57% 증가했습니다. 순이익은 -114.2M로, -22.73% 감소했습니다.

재무제표

어닝 서프라이즈

MeiraGTx가 Aug 13, 2026에 분기 실적을 발표했습니다:
  • 매출 $293K 예상치 하회 $0, 및 -84.79% 전년 대비 감소.
  • EPS 2.52 예상치 상회 2.94, 및 625.00% 전년 대비 성장.

다음 실적 발표

MeiraGTx의 실적 발표 예정일은 Nov 12, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드
news image

2주 전 · Simply Wall St.

What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?

MeiraGTx Holdings (NasdaqGS:MGTX) announced two senior leadership appointments, adding executives with extensive global pharmaceutical development and manufacturing experience. The company reported a ...

news image

2주 전 · MT Newswires

MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says

MeiraGTx (MGTX) is moving closer to becoming a commercial-stage company, with two potential first-in

news image

2주 전 · Zacks

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

MeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

news image

2주 전 · Zacks

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

news image

3주 전 · Zacks

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1